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http://dx.doi.org/10.1016/j.hkjn.201
1561-5413/Copyright ª 2015, Hong KoAbstract Vancomycin-resistant enterococci have emerged as a global health care threat and
their occurrence in peritoneal dialysis-related peritonitis is a challenging condition for ne-
phrologists because the treatment options are limited. In this review, we will discuss the es-
tablished efficacy of linezolid, quinupristin/dalfopristin (Q/P), daptomycin, and the
potential use of tigecycline in treating this condition. Because experience in treating this con-
dition is extremely limited and there is a lack of well-constructed clinical trials on different
treatment options, case reports/series were adopted for descriptive analysis. The treatment
strategy in olden days involved using Q/P (switching to linezolid in case of treatment failures),
whereas recent case reports have described successful use of daptomycin with preservation of
the dialysis catheter in all cases. However, more studies are required to confirm the superiority
of any one of these options in treating this specific condition.
抗萬古黴素腸球菌(vancomycin-resistant Enterococcus)已發展成一個全球性的公共衛生威脅,其
所導致的腹膜透析相關腹膜炎基於治療選項有限,對腎科醫生更是一大挑戰。在本文中我們將回
顧linezolid、quinupristin/dalfopristin (Q/P)、及daptomycin對此病的功效,並探討tigecycline的
潛在角色。基於相關臨床研究與治療經驗的不足,目前這方面的資料主要來自個案報告/系列。我
們大致可見,過去的治療策略從Q/P發展至linezolid;而近年來則出現關於成功使用daptomycin的
個案報告,所有個案的透析導管均得以保存。至於何種治療方案佔優,仍然有待更多研究的進一步
證實。t of Medicine and Geriatrics, United Christian Hospital, 130 Hip Wo Street, Kwun Tong, Kowloon,
ion.
il.com (C.-k. Lam).
5.03.003
ng Society of Nephrology Ltd. Published by Elsevier Taiwan LLC. All rights reserved.
Peritoneal dialysis-associated peritonitis 51Introduction
Enterococcus is a Gram-positive, catalase-negative,
nonspore-forming facultative anaerobic bacterium that
lives symbiotically with Gram-negative bacteria in the
gastrointestinal (GI) tract.1 To date, nearly 30 different
species have been identified, however, most infections are
caused by two strainsdEnterococcus faecalis and Entero-
coccus faecium.
Although broad-spectrum antibiotics and increase in
stomach pH may favor the outgrowth of Enterococcus
individually, antibiotic resistance may also be acquired
through plasmid-mediated transmission,2 which is a serious
threat. Antibiotic resistance has emerged stepwise, starting
with ampicillin resistance first, followed by resistance to
vancomycin and teicoplanin. Reports of linezolid-resistant
Enterococcus have also been published in the past
decade,3 reflecting the need for developing a newer anti-
biotics strategy.
Vancomycin-resistant Enterococcus (VRE) was first re-
ported in France and in the United Kingdom in 1986.4 In-
fections to various organ systems were noted following its
discovery and outbreaks had been reported across the
continents.5,6 Peritonitis associated with continuous
ambulatory peritoneal dialysis (CAPD) caused by VRE was
first described in the early 1990s. In a large series, nine
patients diagnosed with CAPD peritonitis caused by VRE
were treated by intravenous (IV) chloramphenicol. The
remaining patients in that series were treated with beta-
lactams, although their efficacies are not yet clearly
demonstrated. Because of lack of effective treatment, in
most cases, the Tenckhoff catheter had to be removed7 and
only one case had the PD successfully resumed.
In Hong Kong, the prevalence of CAPD peritonitis caused
by VRE is low. Yip et al8 from Hong Kong reported a single-
center retrospective review of CAPD peritonitis. From 1995
to 2009, 1421 episodes of peritonitis were diagnosed, of
which 29 episodes (2.0%) were attributed to single-
organism Enterococcus. The overall rate of ampicillin
resistance was 41.4% and no VRE-related infection was
found.8 However, it was expected that the rate will in-
crease in the future because the use of vancomycin in
incident PD patients infected with resistant bacteria is on
the rise and the prior use of vancomycin is a well-known risk
factor for developing VRE infections, besides other risk
factors including debilitating conditions such as immuno-
suppression and multiple comorbidity, close proximity to
VRE carriers, and long hospital stay. In other localities, the
reported rate of VRE infections among all the CAPD peri-
tonitis was as high as 21%.1
The International Society for Peritoneal Dialysis (ISPD)
consensus guideline on PD-related infections suggested the
use of linezolid, quinupristin/dalfopristin (Q/P), or dapto-
mycin to treat VRE-related CAPD peritonitis.9 In this review,
we will discuss available evidence on the efficacy of various
antibiotics in treating such condition.
Quinupristin/dalfopristin
Q/P (30:70) is a streptogramin agent. Both active compo-
nents have bactericidal activity and in combination, theyexhibit excellent synergistic effects. Q/P has been shown to
be effective in treating various Gram-positive organisms
including staphylococci, E. faecium, Streptococcus pneu-
moniae, Streptococcus pyogenes, Streptococcus aga-
lactiae, viridans streptococci, Clostridium perfringens, and
Peptostreptococcus spp., etc., as well as against resistant
strains such as methicillin-resistant Staphylococcus aureus
(MRSA) and VRE.10 However, its use against VRE is limited to
E. faecium because E. faecalis has much higher minimum
inhibitory concentration (MIC) of Q/P than that of E.
faecium.11
The pharmacokinetic profile of a single IV dose of Q/P
(7.5 mg/kg) has been studied in PD patients and healthy
volunteers. Plasma and dialysate were assayed for com-
pounds and metabolites. It was found that Q/P was pri-
marily excreted through hepatic metabolism and there was
no significant difference in various pharmacokinetic pa-
rameters between the healthy volunteers and renal failure
patients on PD. It is important to note that dialysate con-
centrations of the parent drug and most metabolites were
below the MICs and the dialysis clearance was insignificant.
Because of its poor peritoneal penetration, IV dosing alone
is probably inadequate for CAPD peritonitis.12
Use of Q/P in VRE-related CAPD peritonitis was first
described by Lynn et al11 who reported successful treat-
ment using Q/P for three PD patients with this condition.
These patients were treated by IV Q/P alone or in combi-
nation with intraperitoneal (IP) Q/P. The IV Q/P dose was
10e20 mg/kg/d in two divided doses, whereas the IP Q/P
dose of 25 mg/L given in an alternate bag was extrapolated
from the maximal serum value when the drug was admin-
istered intravenously. One patient relapsed after treatment
for 16 days and the Tenckhoff catheter was removed. This
patient was treated for another 14 days with antibiotics.
Catheters were also not preserved in the remaining two
cases, which were removed before the Q/P treatment or
changed after the end of antimicrobial therapy. The
treatment duration ranged from 14 days to 16 days and no
significant side effects were reported. However, the ratio-
nale behind the simultaneous use of IV and IP routes instead
of IP route alone was not provided.
A more recent case report from Korea described another
case of using Q/P to treat CAPD peritonitis caused by VRE.
However, the combination therapy given to the patient
included Q/P, ampicillinesulbactam, streptomycin, and
trimethoprimesulfamethoxazole.13
Side effects of Q/P include peripheral vein irritation,
arthralgia, myalgia, GI upset, elevated creatinine kinase
level, and deranged liver function. It inhibits the cyto-
chrome P450 3A4 isoenzyme and would probably involve
many drug interactions.
To our knowledge, at the time of this writing, there is no
further case report/series published supporting the use of
Q/P in CAPD peritonitis caused by VRE other than these two
aforementioned reports.Linezolid
Linezolid is the first commercially available oxazolidinone
antibacterial agent capable of treating various infections
caused by Gram-positive resistant organisms including
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pneumococci. This has demonstrated antibacterial activity
against vancomycin-resistant E. faecalis and E. faecium.
Thus, it is an excellent and a much needed alternative to
Q/P for comprehensive enterococcal coverage.
Linezolid is available as IV and oral formulas with almost
100% bioavailability by the oral route. No dosage adjust-
ment is required in any degree of renal insufficiency. As
much as 30% of the drug is removed in a 3-hour hemodialysis
(HD) regimen, but no pharmacokinetic data are available on
peritoneal removal. When administered 600 mg two times a
day, the peritoneal concentration in PD patients was
consistently above the MIC of susceptible enterococci
(2 mg/mL).14 By contrast, dialysate availability was com-
parable after either IV or oral administration and its con-
centration was found to be similar to the serum
concentration.15
Various reports used the IV dose of 600 mg two times a
day, with the treatment duration ranging from 14 days to 21
days.14e18 Catheters were removed in a significant propor-
tion of patients due to various reasons. Table 1 presents the
summary of clinical data of the reported cases. The
aforementioned dosage of linezolid is supported by its
package insert, which suggests a dose of 600 mg two times a
day both orally and intravenously for serious infections
including those caused by VRE; the treatment duration
should be 14e28 days, although no recommendation spe-
cifically on peritonitis has been mentioned.20 By contrast,
the ISPD guideline on peritonitis treatment for pediatric
patients suggests a dose of 600 mg two times a day for
children older than 12 years of age.21 Therefore, the line-
zolid dosage recommendation of 200e300 mg daily for
treating susceptible CAPD peritonitis in “ISPD guideline on
PD related infections recommendations: 2010 update” may
need to be further verified.9
Linezolid-resistant VRE can be a concern when treating
serious infection caused by VRE. Gonzales et al3 reported
that one of 45 (2.2%) VRE isolated was resistant to line-
zolid3; in addition, the manufacturer has also reported a
rate of 1.2% (2/169 isolates). This increase in resistance can
be attributed to the prolonged use of antibiotics, under the
compassionate-use program.22 It was therefore suggested
that testing of linezolid susceptibility is necessary before
initiating treatment as resistance was shown to be associ-
ated with treatment failure in three of five cases.
Linezolid is generally well tolerated with minor side ef-
fects including GI upset, headache, and taste alteration.Table 1 Summary of case reports of treatment using linezolid.
Dosage Duration Concurrent
infection
DePestel et al14 600 mg bd oral 2 wk Nil
Allcock et al15 600 mg bd IV 23 d Candida
Unal et al16 600 mg bd IV 15 d Nil
Bailey et al17 600 mg bd IV 3 wk Candida
Yang et al18 600 mg bd IV 2 wk Nil
Song et al19 600 mg bd IV
then oral
3 wk Nil
IP Z intraperitoneal; IV Z intravenous; bd Z twice a day.Serious adverse effects reported are myelosuppression,
peripheral and optic neuropathy, and serotonin syndrome if
coadministered with serotonergic agents.
Daptomycin
Daptomycin is a cyclic lipopeptide, which demonstrated
rapid concentration-dependent bactericidal activity
against almost all Gram-positive pathogens. Besides, it has
also been shown to have higher efficacy in eradicating MRSA
embedded in biofilms, compared with other agents
including tigecycline, vancomycin, and linezolid.23 Because
Enterococcus was associated with biofilm formation, such
capability may be of potential benefit in PD-associated
peritonitis as biofilm formation around the catheter may
lower the chance of salvaging the PD catheter during the
peritonitis episode. It is extensively protein bound and is
78% urine excreted. Specifically, it diffuses poorly into PD
fluid, and therefore, the IP route for treating CAPD peri-
tonitis is necessary for better drug concentration.24 Goe-
decke et al25 published pharmacokinetic data of
daptomycin administered intravenously at a dose of 6 mg/
kg to a patient on automated PD. Their results indicated
that therapeutic concentrations of daptomycin were
consistently above MIC90 of VRE in blood and peritoneal
fluid. However, it should be noted that the dialysate con-
centration 24 hours after the infusion was just above the
MIC90 of VRE, and therefore, a single daily IV dose may not
be adequate to provide 24-hour coverage for PD peritonitis.
Although the peritoneal distribution of daptomycin may be
limited, the peritoneal absorption was apparently
adequate. Bahte et al26 have demonstrated that the ther-
apeutic serum level of daptomycin was 10 times above the
MIC90 of MRSA after IP administration of a single dose of
7 mg/kg (remaining for 12 hours intraperitoneally).26
According to the manufacturer, daptomycin degrades in
5% dextrose solutions at a rate of 15e20% within 24 hours at
room temperature. It is therefore recommended to perform
dwelling right after mixing with PD fluid. Experiments on
compatibility of PD fluids (Physioneal and Nutrineal) have
been performed on various daptomycin concentrations
including 50 mg/L, 100 mg/L, and 200 mg/L, which were
kept at various temperatures (4C, 25C, and 37C). At 24
hours after mixing with PD solutions at 25C, the concen-
tration of daptomycin recovered was 85e102% of the initial
concentration, whereas for the sample mixed at 4C, the
recovery was 93e102%. If the duration was shortened to 6Concurrent
treatment
Initial
Response
Catheter
removal
Relapse
IP gentamicin Good No Not mentioned
IV levofloxacin Good Yes Not mentioned
Nil Good Yes Not mentioned
Fluconazole Poor Yes Not mentioned
Nil Good No No
Nil Good No No
Table 2 Summary of the characteristics of various antibiotics.
Antibiotic Bacterial killing
effect
(bactericidal vs.
bacteriostatic)
Compatibility
with PD
solution
Preferred
route
of
administration
(IV/PO/IP)
Successful
treatment
reported
Estimated
3-wk treatment
cost (HK dollars)a
ISPD
guideline-recommended
treatment9
Q/P Bactericidal but
limited to
Enterococcus
faecium
Yes
(case report)
IV  IP Yes 65-kg patient Yes
(10e20 mg/kg/d) US$50,00035
Linezolid Bacteriostatic to
most pathogens
No data IV/PO Yes 20,000 Yes
(600 mg bd)
Daptomycin Bactericidal Yes IP Yes 26,500 Yes
(20 mg/L q.i.d.)
Tigecycline Bacteriostatic to
most pathogens
No data IV No 18,000 No
(50 mg bd)
IP Z intraperitoneal; ISPD Z International Society for Peritoneal Dialysis; IV Z intravenous; PD Z peritoneal dialysis; PO Z per oral;
Q/P Z quinupristin/dalfopristin; bd Z twice a day; q.i.d. Z 4 times a day.
a Best available information from the literature if local cost not available.
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ranged from 93% to 116%.27 The compatibility test on
Extraneal has been performed previously, however, there is
a lack of report due to severe interference on the assay,
probably due to the icodextrin molecule. It was therefore
concluded that daptomycinedextrose mixture at room
temperature was probably stable up to 6 hours, although
the best practice may still be an immediate dwelling after
mixing the drug. Although the stability of daptomycin in
Extraneal has not yet been reported, its in vitro bacteri-
cidal activity has been confirmed experimentally, which
showed a superior antimicrobial activity of daptomycin
compared with vancomycin when mixed with Extraneal for
killing MRSA.28
Reports on the use of daptomycin in PD peritonitis
caused by VRE are limited to case reports. Hassoun et al29
reported the first case of using IP daptomycin in treating
this condition. The regimen administered was two IP doses
of 15 mg/kg daptomycin 10 days apart and the treatment
was successful without need for Tenckhoff catheter
removal. A series of two cases had also been reported and
the regimen was a continuous dose of daptomycin (20 mg/
L) administered every 4 hours for 10e14 days. IP alteplase
was also administered and the catheters were preserved.26
In all cases reported so far, daptomycin was mixed with
dextrose solution. We have also used IP daptomycin to treat
PD peritonitis caused by VRE (not published). Because of
limitations in the PD fluid exchange schedules and the need
for Extraneal to ensure secured ultrafiltration, a schedule
for dextrose solution exchange every 5e6 hours three times
a day and Extraneal dwell for 8 hours was adopted. The
loading and maintenance doses were 200 mg/L and 20 mg/
L, respectively. After 3 weeks of treatment, catheter
preservation was achieved; in addition, fibrinolytic treat-
ment was not given in this case. No relapse was noted after
27 days of completing daptomycin treatment; however, the
patient passed away due to another event at that juncture.
Daptomycin is generally well tolerated, but causes
myopathy in some cases. Therefore, routine monitoring of
the creatinine kinase level is necessary.24Tigecycline
Tigecycline is the first approved glycylcycline with broad-
spectrum antimicrobial activity against Gram-positive,
Gram-negative, and anaerobic bacteria. Tigecycline has
been studied for the treatment of complicated skin in-
fections and skin structure infections, intra-abdominal in-
fections, and pneumonia. Its activity against VRE has also
been demonstrated with more than 99% in vitro suscepti-
bility30,31 and its use in PD peritonitis caused by MRSA has
been tried successfully.32 In a recent meta-analysis evalu-
ating its efficacy and side effects, the effectiveness of
tigecycline in treating Enterococcus infection was found to
be superior than control antibiotics, whereas its use for
treating complicated intra-abdominal infection was less
efficacious (both were statistically nonsignificant).33
In vitro studies have shown that tigecycline exhibits a
time-dependent pattern of bactericidal activity and the
dose requires no adjustment in patients with severe renal
impairment. It was not effectively removed by HD, and
therefore, additional dosage was not required in HD pa-
tients.34 Although the use of tigecycline specifically against
PD peritonitis caused by VRE has not been reported so far, it
is a promising alternative especially if resistance to other
newer antibiotics has been developed or in case of un-
availability of other effective treatments. Table 2 presents
the summary of the characteristics of various antibiotics.
Other agents
Ceftaroline
Ceftaroline fosamil belongs to the group of cephalosporin
antibiotics, and has demonstrated excellent activity against
MRSA. It has been approved by the U.S. Food and Drug
Administration for use in the treatment of acute bacterial
skin and skin structure infections and community-acquired
bacterial pneumonia. It has also demonstrated antibacte-
rial activity against VRE especially against vancomycin-
54 C.-k. Lam et al.resistant E. faecalis. However, it is much less effective
against E. faecium, although this pathogen is vancomycin
susceptible.36 Although this drug has potential use in VRE,
its efficacy in PD peritonitis, peritoneal distribution after
systemic IV administration, compatibility in PD solution,
and systemic absorption after IP injection have not been
well studied and reported. Thus, more studies are required
to address all these issues.
Summary
PD peritonitis caused by VRE is a potential threat to the
health care system and patient management because of
limited experience in the treatment options in managing
this condition. When comparing the four drugs mentioned
here, daptomycin appears to be superior because it can be
administered intraperitoneally and the dialysis catheters
were all preserved in the reports published so far. However,
because daptomycin may have inadequate peritoneal con-
centration, the drug may not be useful if IP route is not
feasible after catheter removal for initial poor response.
Another major problem on the use of these antibiotics is
the cost. None of the single agents reviewed in this article
is relatively cheaper and most importantly, they may not be
readily available in all the clinical settings either due to
economic or legal factors. Finally, more clinical data
comparing different forms of treatment are needed while
policies to increase accessibility of these agents are also
required.
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